Immune cell combo tackles tough autoimmune conditions

NCT ID NCT06991114

Recruiting now Disease control Sponsor: Artiva Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 30 times

Summary

This study tests a new treatment for people with certain autoimmune diseases (rheumatoid arthritis, Sjögren's disease, myositis, and scleroderma) that have not responded to standard therapies. The treatment combines AlloNK, a type of immune cell from donated cord blood, with rituximab, a drug that targets B cells. The goal is to see if this combination is safe and can reduce disease activity. About 90 adults will take part in this early-stage trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Artiva Investigational Site Arlington
RECRUITING

Arlington, Texas, 76012, United States
Artiva Investigational Site Aventura
RECRUITING

Aventura, Florida, 33180, United States
Artiva Investigational Site Brescia
RECRUITING

Brescia, 25125, Italy
Artiva Investigational Site Bucharest
RECRUITING

Bucharest, 50474, Romania
Artiva Investigational Site Bucuresti
RECRUITING

Bucharest, 20125, Romania
Artiva Investigational Site Charlotte
RECRUITING

Charlotte, North Carolina, 28207, United States
Artiva Investigational Site Charlotte
RECRUITING

Charlotte, North Carolina, 28625, United States
Artiva Investigational Site Covina
RECRUITING

Covina, California, 91723, United States
Artiva Investigational Site Hixson
RECRUITING

Hixson, Tennessee, 37343, United States
Artiva Investigational Site Iowa
RECRUITING

Iowa City, Iowa, 52242, United States
Artiva Investigational Site Jupiter
RECRUITING

Jupiter, Florida, 33458, United States
Artiva Investigational Site Katy
RECRUITING

Katy, Texas, 77494, United States
Artiva Investigational Site Los Alamitos
RECRUITING

Los Alamitos, California, 90720, United States
Artiva Investigational Site Marseille
RECRUITING

Marseille, 13005, France
Artiva Investigational Site Mesquite
RECRUITING

Mesquite, Texas, 75150, United States
Artiva Investigational Site Montpellier
RECRUITING

Montpellier, 34090, France
Artiva Investigational Site Munchen
RECRUITING

München, 80336, Germany
Artiva Investigational Site Phoenix
RECRUITING

Phoenix, Arizona, 85037, United States
Artiva Investigational Site Plantation
RECRUITING

Plantation, Florida, 33324, United States
Artiva Investigational Site Sevila
RECRUITING

Seville, 41701, Spain
Artiva Investigational Site Sofia
RECRUITING

Sofia, 1612, Bulgaria
Artiva Investigational Site Toulouse
RECRUITING

Toulouse, 31059, France
Artiva Investigational Site Tuscaloosa
RECRUITING

Tuscaloosa, Alabama, 35406, United States
Artiva Investigational Site Vila Nova De Gaia
RECRUITING

Vila Nova de Gaia, 4434, Portugal
Artiva Investigational Site Willowbrook
RECRUITING

Willowbrook, Illinois, 60527, United States
Artiva Investigational Site Woodland
RECRUITING

Woodland, Texas, 77382, United States

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC INFLAMMATORY MYOPATHIES (IIMS) IIM MYOSITIS REFRACTORY RHEUMATOID ARTHRITIS (RA) RHEUMATOID ARTHRITIS (RA SCLERODERMA SJOGREN SYNDROME SJOGREN SYNDROME SJOGRENS DISEASE SJOGRENS DISEASE SYSTEMIC SCLEROSIS (SSC) SYSTEMIC SCLEROSIS (SSC)